NCT03673020View on ClinicalTrials.gov

Phase 1a Study to Evaluate Immunogenicity of ASV®

PHASE1CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

February 3, 2021

Study Completion Date

February 3, 2021

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL

ASV® AGEN2017 + QS-21 Stimulon® adjuvant

Neoantigen Vaccine

Trial Locations (1)

33136

School of Medicine at the University of Miami, Miami

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Agenus Inc.

INDUSTRY